Anesiva Announces Submission Of Supplemental New Drug Application For Zingo(TM) To Reduce Pain Associated With Needle Insertion Procedures In Adults
Anesiva, Inc. (Nasdaq: ANSV) announced that the company has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) to expand the indication for Zingo to treat the pain associated with peripheral IV insertions and blood draws in adults.
More: continued here